Skip Navigation

Japanese Journal of Clinical Oncology 2004 34(6):337-341; doi:10.1093/jjco/hyh064
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sheen, W.-C.
Right arrow Articles by Lin, Y.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheen, W.-C.
Right arrow Articles by Lin, Y.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Foundation for Promotion of Cancer Research

A Modified Low-dose Regimen of Mitoxantrone and Prednisolone in Patients with Androgen-independent Prostate Cancer

Wen-Chyi Sheen, Jen-Shi Chen, Hung-Ming Wang, Tsai-Shen Yang, Chuang-Chi Liaw and Yung-Chang Lin+

Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tun-Hwa North Road, Taipei, Taiwan

Background: We conducted this retrospective study to analyze a modified dose schedule of mitoxantrone and prednisolone (MP) in patients with androgen-independent prostate cancer.

Methods: From June 1997 to April 2002, 28 patients were enrolled. Their median age was 69 years (range, 58–79 years). The median duration of hormonal therapy was 30 months (range, 6–84 months). The median performance status was 2. Sixteen of the patients had bone disease only. The chemotherapy consisted of 8 mg/m2 mitoxantrone by intravenous infusion every 3 weeks and 10 mg prednisolone orally twice per day. WHO response criteria, prostatic-specific antigen (PSA), pain and performance status were used to assess the response.

Results: The median number of treatment cycles was six (range, 2–20). Nine (32.1%) and 15 patients (53.8%) had ≥80% and ≥50% reduction in serum PSA level, respectively. Of 16 patients using narcotics, five (31.3%) had a ≥50% reduction in narcotics consumption compared with the baseline. Nine patients (32.1%) showed improved performance. For 12 patients with measurable disease, only two (16.7%) showed a partial response. Grade 3–4 toxicities included neutropenia (three patients), anemia (three patients) and vomiting (one patient). The median survival was 12 months and the median time to PSA progression was 4 months.

Conclusions: This modified regimen is feasible for palliative intent. The toxicity of this regimen is manageable. Exploring further combinations of this regimen with novel agents against androgen-independent prostate cancer is warranted.

+ For reprints and all correspondence: Yung-Chang Lin, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tun-Hwa North Road, Taipei 105, Taiwan. E-mail: yclinof{at}adm.cgmh.org.tw


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.